ReviewPhytotherapy research : PTR2026
Natural Products as Modulators of ABC Transporters in Breast Cancer.
Review in Phytotherapy research : PTR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Natural-Origin Compounds as Future Precision Partners in Combination Cancer Therapy.Medicina (Kaunas, Lithuania) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer remains a significant global health challenge, with high incidence and mortality rates despite advancements in early detection and treatment. Multidrug resistance (MDR), particularly in aggressive subtypes like triple-negative breast cancer (TNBC), continues to hinder effective therapy. MDR is primarily driven by the overexpression of ATP-binding cassette (ABC) transporters such as P-gp, BCRP, and MRP1. ABC transporters actively efflux chemotherapeutic agents, reducing their efficacy and complicating treatment outcomes. This narrative review explores the potential of natural products to modulate ABC transporters as a strategy to mitigate MDR in breast cancer. A literature search was conducted across Ovid Medline, PubMed, Scopus, Embase, Web of Science, and EBSCOhost. Articles underwent a two-stage screening process (title and abstract and full text), with additional manual searches of reference lists. The results show that natural products derived from plants can inhibit ABC transporters through suppression of protein expression, downregulation of mRNA expression, and inhibition of drug efflux functions. Additionally, they target indirect regulatory pathways, such as NF-κB, YB-1, PI3K/Akt, and ATPase activity, further contributing to the reversal of MDR. These compounds work synergistically with chemotherapeutic agents like doxorubicin and paclitaxel to enhance drug retention and efficacy while reducing toxicity. This multifaceted approach highlights the potential of natural products as valuable adjunct therapies in breast cancer treatment, offering new strategies to overcome drug resistance and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.